Talimogene laherparepvec

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

MelanomaSoft Tissue SarcomaSarcomaLeiomyosarcomaAnaplastic Large Cell Lymphoma, ALK-Negative

191 competitors in Melanoma

#DrugCompanyPhaseTrials

1

Keytruda

Merck & Co.

Phase 3

952

Opdivo

Bristol-Myers Squibb

Phase 3

1123

Mekinist

Novartis

Phase 3

454

Cotellic

Roche

Phase 3

215

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 3

396

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

357

Taxol

Teva

Phase 3

138

Mektovi

Pfizer

Phase 3

129

Tecentriq

Roche

Phase 3

1110

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

28Show 34 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Melanoma14 trials

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02965716·43 enrolled

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

Completed·Amgen·Phase 1/2·NCT01740297·217 enrolled

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

Completed·BBioVex Limited·Phase 3·NCT01368276·31 enrolled

Show 11 more trials

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

Completed·Amgen·Phase 2·NCT02366195·112 enrolled

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

Recruiting·UUniversity of Louisville·Phase 2·NCT03842943·28 enrolled

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

No longer available·Amgen··NCT02147951

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

Completed·BBioVex Limited·Phase 2·NCT00289016·50 enrolled

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

Terminated·Amgen·Phase 3·NCT02263508·713 enrolled

Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

Completed·Amgen·Phase 2·NCT02211131·150 enrolled

Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma

No longer available·Amgen··NCT02297529

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Withdrawn·TTriHealth Inc.·Phase 2·NCT03972046

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

Completed·Amgen·Phase 2·NCT04068181·72 enrolled

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

Completed·Amgen·Phase 1·NCT03064763·18 enrolled

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Completed·BBioVex Limited·Phase 3·NCT00769704·437 enrolled

Breast Cancer5 trials

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT04185311·6 enrolled

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02658812·11 enrolled

Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer

Completed·SSOLTI Breast Cancer Research Group·Phase 1·NCT03802604·28 enrolled

Show 2 more trials

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT03554044·20 enrolled

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT02779855·50 enrolled

Sarcoma3 trials

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

Active, not recruiting·JJohn Rieth·Phase 1/2·NCT04599062·8 enrolled

TVEC and Preop Radiation for Sarcoma (4 ml Dose)

Completed·UUniversity of Iowa·Phase 1/2·NCT02453191·30 enrolled

A Phase II Study of Talimogene Laherparepvec (T-VEC) Administered Concurrently With the Anti-PD1 Monoclonal Antibody Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03069378·41 enrolled

Pancreatic Cancer2 trials

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

Completed·BBioVex Limited·Phase 1·NCT00402025·17 enrolled

Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

Completed·—·Phase 1·NCT03086642·10 enrolled

Squamous Cell Carcinoma2 trials

Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin

Terminated·RRutgers, The State University of New Jersey·Phase 1·NCT04163952·5 enrolled

Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)

Completed·Amgen·Phase 1·NCT02626000·36 enrolled

16 more indications

ART1 trial

An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)

Completed·BBioVex Limited·Phase 2·NCT02574260·3 enrolled

Malignancies1 trial

Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies

Completed·—·Phase 1·NCT03663712·28 enrolled

CNS Tumors1 trial

Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

Completed·Amgen·Phase 1·NCT02756845·15 enrolled

Locally Advanced Head and Neck Cancer1 trial

Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

Terminated·BBioVex Limited·Phase 3·NCT01161498·5 enrolled

Radiation Therapy1 trial

Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT03300544·3 enrolled

Colorectal Cancer1 trial

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Completed·Amgen·Phase 1·NCT03256344·36 enrolled

Tumour1 trial

TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)

Completed·RRoyal Marsden NHS Foundation Trust·Phase 1/2·NCT03555032·15 enrolled

Pleural effusion1 trial

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT03597009·1 enrolled

Merkel Cell Carcinoma1 trial

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02819843·19 enrolled

Pembrolizumab1 trial

Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

Completed·Amgen·Phase 1/2·NCT02509507·127 enrolled

Kaposi Sarcoma1 trial

Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04065152·20 enrolled

Trial1 trial

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

Completed·Amgen·Phase 2·NCT02014441·61 enrolled

Bladder Transitional Cell Carcinoma1 trial

Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma

Withdrawn·UUniversity of California, San Francisco·Phase 1·NCT03430687

Leiomyosarcoma1 trial

A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02923778·40 enrolled

Anaplastic Large Cell Lymphoma, ALK-Negative1 trial

A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02978625·68 enrolled

Soft Tissue Sarcoma1 trial

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

Active, not recruiting·JJohn Rieth·Phase 2·NCT06660810·2 enrolled

Details

Drug Info

Related News